Go to deals
Healthcare | TMT

HD Clinical Ltd. has been acquired by NEXUS AG

NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.

HD Clinical was founded in 2005 by a group of clinicians to build an electronic clinical record system starting from departmental requirements and delivering management data derived from real-world patient information. This was a departure from the historic top-down approach of electronic patient record (EPR) systems, which were essentially upgraded patient administration systems with ‘one-size-fits-all’ clinical functionality bolted on. For 17 years, HD Clinical has been delivering digital clinical solutions to healthcare organizations around the world. The company’s solutions are used by 146 organizations across the globe, joining up healthcare organizations and hospital departments to improve the patient experience. The HD Clinical approach is designed to capture maximum engagement from clinical teams by meeting their needs and recognizing the specific requirements of each specialty. Their software and hardware are designed by their in-house team in the HD Clinical UK office.

Nexus AG provides innovative software solutions that allow users at healthcare facilities to focus on what really matters. Their goal is to offer all departments in hospitals, psychiatric wards and rehabilitation and residential institutions the best solution to the challenges they face every day.

Oaklins S&W, one of Oaklins’ member firms in the UK, acted as lead the advisor to HD Clinical’s shareholders on the sale of the business. After winning a competitive pitch process, the team advised on all aspects of the transaction, from initial buyer research and preparation for sale to the preparation of marketing documents, leading negotiations and buyer meetings, managing due diligence and general project management throughout the deal.

Parties
“The Oaklins team was able to successfully navigate us through what turned out to be an incredibly complex and challenging transaction process. The level of attention, communication and availability exceeded our expectations. The team which led the deal was invaluable to us and provided the required support and advice while keeping the momentum of the deal going. Their drive and determination to get the right deal for the shareholders was exceptional. I look forward to working with them again in the, hopefully, not too distant future.”

Dr. Clive Layton

Founder, HD Clinical

Talk to the deal team

Prashant Dhokia

Senior Manager
Cambridge, United Kingdom
Oaklins S&W

Related deals

MEDIK Hospital Design Group has been acquired by STERIS
Construction & Engineering Services | Healthcare

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Learn more
Niscon Inc. has been acquired by SGPS ShowRig
TMT

Niscon Inc. has been acquired by SGPS ShowRig

Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.

Learn more
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Healthcare

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Learn more